Cargando…

The impact of primary biliary cholangitis on non-alcoholic fatty liver disease

BACKGROUND: The impact of chronic cholestatic liver diseases such as primary biliary cholangitis (PBC) on non-alcoholic fatty liver disease (NAFLD) has yet to be described. OBJECTIVES: To document and compare the severity and course of liver disease in patients with NAFLD/PBC versus NAFLD alone. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iluz-Freundlich, Daniel, Uhanova, Julia, Grubert Van Iderstine, Micah, Minuk, Gerald Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2020
Materias:	Original Articles: Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908858/ https://www.ncbi.nlm.nih.gov/pubmed/32541239 http://dx.doi.org/10.1097/MEG.0000000000001782

Ejemplares similares

Liver disease referrals to an urban, hospital‐based hepatology outpatient clinic over the past 25 years
por: Grubert Van Iderstine, Micah, et al.
Publicado: (2019)

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
por: Harms, Maren H, et al.
Publicado: (2020)

Barriers to implementation of stratified care in primary biliary cholangitis: a scoping exercise
por: Corrigan, Margaret, et al.
Publicado: (2019)

The Psychological and Financial Impact of Long-distance Travel for Liver Transplantation
por: Peretz, David, et al.
Publicado: (2020)

Disease burden of primary biliary cholangitis and associated pruritus based on a cross-sectional US claims analysis
por: Gungabissoon, Usha, et al.
Publicado: (2022)

Prevalence of frailty in patients with non-cirrhotic non-alcoholic fatty liver disease
por: Naimimohasses, Sara, et al.
Publicado: (2022)

Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome
por: Asfari, Mohammad Maysara, et al.
Publicado: (2020)

Home-based exercise in patients with refractory fatigue associated with primary biliary cholangitis: a protocol for the EXerCise Intervention in cholesTatic LivEr Disease (EXCITED) feasibility trial
por: Freer, Alice, et al.
Publicado: (2021)

Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease
por: Nascimbeni, Fabio, et al.
Publicado: (2016)

Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease
por: Sayiner, Mehmet, et al.
Publicado: (2016)

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
por: Hardy, Timothy, et al.
Publicado: (2017)

Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease
por: Mehta, Rohini, et al.
Publicado: (2016)

Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss
por: Hallsworth, Kate, et al.
Publicado: (2011)

Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease
por: Wood, Kayleigh L, et al.
Publicado: (2015)

Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review
por: Kenneally, Susan, et al.
Publicado: (2017)

Feasibility, safety and tolerability of the CREB-binding protein/β-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study
por: Kimura, Masamichi, et al.
Publicado: (2022)

A novel prognostic model for transplant-free survival in primary sclerosing cholangitis
por: de Vries, Elisabeth M, et al.
Publicado: (2018)

Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational study
por: Zhang, Mingyuan, et al.
Publicado: (2019)

Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt
por: Tomah, Shaheen, et al.
Publicado: (2021)

Patient disease knowledge, attitudes and behaviours related to non-alcoholic fatty liver disease: a qualitative study
por: Tincopa, Monica A, et al.
Publicado: (2021)

Prevalence of non-alcoholic fatty liver disease in overweight and obese children seeking ambulatory healthcare in Nairobi, Kenya
por: Mburu, Anne Njeri, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients
por: Uhanova, Julia, et al.
Publicado: (2016)

RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease
por: Afonso, Marta B, et al.
Publicado: (2021)

Prevalence, risk factors and metabolic profile of the non-obese and obese non-alcoholic fatty liver disease in a rural community of South Asia
por: Rahman, M Masudur, et al.
Publicado: (2020)

High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study
por: Duseja, Ajay, et al.
Publicado: (2019)

Relationship between osteoporosis, sarcopenia, vertebral fracture, and osteosarcopenia in patients with primary biliary cholangitis
por: Saeki, Chisato, et al.
Publicado: (2020)

TGF-β2 silencing to target biliary-derived liver diseases
por: Dropmann, Anne, et al.
Publicado: (2020)

Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia
por: Maev, Igor V, et al.
Publicado: (2020)

Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner
por: Trivedi, Palak J, et al.
Publicado: (2018)

Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease
por: Scragg, Jadine, et al.
Publicado: (2021)

Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis
por: Angelini, Giulia, et al.
Publicado: (2023)

Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort
por: Chalmers, Jane, et al.
Publicado: (2019)

Does neutrophil-to-lymphocyte ratio predict 1-year mortality in patients with primary biliary cholangitis? Results from a retrospective study with validation cohort
por: Lin, Lin, et al.
Publicado: (2017)

Duct-to-Duct Biliary Anastomosis Yields Similar Outcomes to Roux-en-Y Hepaticojejunostomy in Liver Transplantation for Primary Sclerosing Cholangitis
por: Al-Judaibi, Bandar, et al.
Publicado: (2015)

MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway
por: Wu, Heng, et al.
Publicado: (2016)

Comparison of laboratory indices of non-alcoholic fatty liver disease for the detection of incipient kidney dysfunction
por: Choi, Jong Wook, et al.
Publicado: (2019)

Effects of sleep quality on non-alcoholic fatty liver disease: a cross-sectional survey
por: Takahashi, Atsushi, et al.
Publicado: (2020)

Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study
por: Tang, Xiaoping, et al.
Publicado: (2022)

Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH)
por: Chawla, Kashmira S, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hb5sd9dvmhlpbbtv4klq5qjd7s